MK-2295

CAS No. 878811-00-8

MK-2295( MK2295 | MK 2295 )

Catalog No. M27996 CAS No. 878811-00-8

MK-2295 is a potent TRPV1 antagonist. MK-2295 can be used in studies about the treatment of chronic pain.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 393 Get Quote
10MG 581 Get Quote
25MG 888 Get Quote
50MG 1242 Get Quote
100MG 1674 Get Quote
500MG 3348 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    MK-2295
  • Note
    Research use only, not for human use.
  • Brief Description
    MK-2295 is a potent TRPV1 antagonist. MK-2295 can be used in studies about the treatment of chronic pain.
  • Description
    MK-2295 is a potent TRPV1 antagonist. MK-2295 can be used in studies about the treatment of chronic pain.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    MK2295 | MK 2295
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    TRP/TRPV Channel
  • Recptor
    JAK1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    878811-00-8
  • Formula Weight
    490.583
  • Molecular Formula
    C27H31FN6O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@@H]1CCCN1c1nc(cc(n1)-c1ccc(F)cc1)N1CCN(C[C@H]1C)c1ncc(cc1C)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Paul Smith, et al. Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp). WO2021076124A1.
molnova catalog
related products
  • BI-749327

    BI-749327 is a high selectivity and orally bioavailable antagonist of TRPC6 (IC50s: 13 nM, 19 nM and 15 nM for mouse, human and guinea pig TRPC6).

  • A-967079

    A potent, selective TRPA1 channel blocker with IC50 of 51 nM and 101 nM for hTRPA1 and rTRPA1, respectively.

  • A 425619

    A 425619 is a potent TRPV1 antagonistsystemic administration of the TRPV1 antagonist, A-425619, reversed the decrease in digging behavior induced by CFA injection, further confirming the role of TRPV1, expressed by knee neurons, in acute inflammatory joint pain.